结直肠癌肝转移d-TACE的结果
|
| study | design | pts. | strategy | RR (%) | mOS mo | PFS mo |
| Martin 2009 | retrosp. | 55 | salvage |
41 mRECIST 6 RECIST |
11 | 8 |
| Huppert 2013 | prosp. | 29 | salvage |
72 mRECIST 0 RECIST |
8 | 5 |
| Akinwande 2016 | prosp. | 15 | various |
73 mRECIST 33 RECIST |
13 | 8 |
RECIST is superior to mRECIST to stratify survival benefit according to response (evaluation of 228 mCRC pts treated with DE-TACE (91%) and Rembx 9%) Akinwande et al. 2016; J Surg Oncol 113:443-8
评估用228个结直肠癌肝转移的d-TACE患者（91%）和根据反应(用DE-TACE（91%）和Rembx方法（9%），RECIST优于mRECIST对生存效益进行分层)Akinwande et al. 2016; J Surg Oncol 113:443-8
RECIST vs. mRECIST in DE-TACE
Peter Hupper t • Thorsten Wenzel • Huber tus Wietholtz Transcatheter Arter ial Chemoembolization (TACE) of Color ectal Cancer Liver M etastases by Ir inotecan-Eluting Microspheres in a Salvage Patient Population. Cardiovasc Intervent Radiol 2014;37:154-64
生存率：整体生存率 vs 无病生存率 vs 肝无病生存率
（Survival: OS vs. PFS vs. hepatic PFS）
| study | design | pts. | strategy | mOS mo | PFS mo |
| Martin 2009 | retrosp. | 55 | salvage | 11 | 8 |
| Fiorentini 2012 | pRCT | DEBIRI 36 | SL | 22 | 7 |
|
|
|
FOLFIRI 38 |
|
15 (p=.03) | 4 (p=.006) |
| Narayanan 2013 | retrosp. | 28 | salvage | 13.3 | 4 |
| Huppert 2013 | prosp. | 29 | salvage | 8 | 5 |
| Iezzi 2015 | retrosp. | 20 | salvage | 7.3 | 4.0 |
| Martin 2015 | prosp. | 30 FOLFOX | various | n.a. | 7.6 |
|
|
|
30 FOLFOX |
|
|
15.3 |
|
|
|
+ DEBIRI |
|
|
|
| Akinwande 2016 | prosp. | 15 | various | 13 | 8 |
|
|
|
|
|
|
|
| cTACE |
|
|
|
8-14 | 3-8 |